Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 91
Filtrar
1.
Diagn Pathol ; 13(1): 50, 2018 Aug 13.
Artículo en Inglés | MEDLINE | ID: mdl-30103782

RESUMEN

BACKGROUND: Cutaneous epithelioid angiomatous nodule (CEAN) is a very rare and relatively recently recognized vascular proliferation characterized usually by minimal cytological atypia and accompanying mitotic activity. As such, CEAN represents an important diagnostic pitfall, which could lead to significant misdiagnosis and unnecessary treatment. METHODS: The clinicopathologic findings of 5 cases of CEAN were reviewed including a unique case with typical findings but also moderate cytologic atypia and brisk mitotic activity in a patient on immunosuppression. RESULTS: The cases were in 3 women and 2 men ranging in age from 18 to 61 years with lesions in the neck (2 cases), upper arm, back and shoulder. In 4 of the cases, the patients did not have any relevant potentially contributory clinical history, and in 1 case the patient was on immunosuppressive treatment. All 5 cases were superficially located within the dermis, well-circumscribed and similarly composed of epithelioid cells displaying minimal (in 4 cases) and moderate (1 case) atypia. The mitotic count ranged from 1 to 3 per 10 high power fields (HPF) in 4 cases and up to 9 per 10 HPF in the immunosuppressed patient. Atypical mitoses were not encountered in any of the cases. Two lesions that were incompletely excised recurred, but none of the patients showed distant metastases. CONCLUSION: While cytologically alarming, CEAN has a characteristic microscopic appearance and if completely excised follows an indolent course.


Asunto(s)
Proliferación Celular , Células Epitelioides/patología , Hemangioma/patología , Neoplasias Cutáneas/patología , Adolescente , Adulto , Biopsia , Diagnóstico Diferencial , Células Epitelioides/inmunología , Femenino , Hemangioma/inmunología , Hemangioma/cirugía , Humanos , Huésped Inmunocomprometido , Inmunosupresores/efectos adversos , Masculino , Persona de Mediana Edad , Índice Mitótico , Recurrencia Local de Neoplasia , Neoplasia Residual , Valor Predictivo de las Pruebas , Estudios Retrospectivos , Neoplasias Cutáneas/inmunología , Neoplasias Cutáneas/cirugía , Resultado del Tratamiento , Adulto Joven
2.
Hum Pathol ; 82: 172-176, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-29702119

RESUMEN

Glomeruloid hemangioma is a rare cutaneous lesion that has been considered as a specific cutaneous marker of POEMS syndrome. Herein, we present the first case of glomeruloid hemangioma associated with TAFRO syndrome, a unique variant of idiopathic multicentric Castleman disease. The patient is a 74-year-old woman presented with fever, cervical lymphadenopathy, thrombocytopenia, bilateral pleural effusions and ascites. Biopsy of the lymph node revealed multicentric Castleman disease-like histology and bone marrow biopsy showed mild reticulin fibrosis, consistent with TAFRO syndrome. The patient simultaneously developed multiple skin lesions, which were histologically confirmed as glomeruloid hemangioma. Multiple immunoglobulin-positive granules were detected in the proliferating endothelial cells. Glomeruloid hemangioma is not specific to POEMS syndrome and can be a manifestation of TAFRO syndrome.


Asunto(s)
Enfermedad de Castleman/patología , Hemangioma/patología , Ganglios Linfáticos/patología , Neoplasias Cutáneas/patología , Anciano , Antineoplásicos Inmunológicos/uso terapéutico , Biopsia , Enfermedad de Castleman/tratamiento farmacológico , Enfermedad de Castleman/inmunología , Femenino , Hemangioma/tratamiento farmacológico , Hemangioma/inmunología , Humanos , Inmunoglobulinas/análisis , Inmunohistoquímica , Ganglios Linfáticos/efectos de los fármacos , Ganglios Linfáticos/inmunología , Rituximab/uso terapéutico , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/inmunología , Esteroides/uso terapéutico , Resultado del Tratamiento
3.
Beijing Da Xue Xue Bao Yi Xue Ban ; 49(3): 495-500, 2017 Jun 18.
Artículo en Chino | MEDLINE | ID: mdl-28628153

RESUMEN

OBJECTIVE: To investigate the clinicopathological features, morphological characteristics, immunophenotypes of littoral cell angioma (LCA) in spleen, and to provide new evidence for making diagnosis and avoiding misdiagnosis. METHODS: Clinicopathological data, histological characteristics of 13 cases of LCA were retrospectively studied and immunohistochemical staining was imposed on the paraffi-nembedded specimens, and 5 cases of cavernous hemangioma, 4 cases of normal littoral cells of spleens were used as control groups, simultaneously. RESULTS: All the 13 LCA patients included 7 males and 6 females, aged from 39 to 70 years with an average of 54. 2 years and a median age of 55 years. Among these tumor patients, 6 cases were accompanied by malignances, benign tumors or inflammation states at abdominal cavities, and 7 cases were accidentally discovered by physical examinations. Grossly, spleens contained solitary or multiple gray red nodules ,which ranged from 0.5 to 6.2 cm in diameter. Histologically, tumors were composed by anastomosing vascular spaces which were lining by plump, rounded to cuboidal littoral cells that extended into vascular lumens. Usually, papillary frameworks that were covered by these cells were also seen extending into the lumens in some areas. Other types of histiocytoid cells were identified in lumens and the sizes were larger than the littoral cells. Both types of cells absented cytologic atypia. Immunohistochemical study demonstrated that the littoral cells in all cases were positive for vascular endothelial and histiocyte markers, such as CD21, CD31, CD68, polyclone FVIII RAg and ERG, while these cells were negative for CD8, CD34, and WT-1. These findings manifested that immunophenotype of littoral cell in LCA distinctive from that in controls. CONCLUSION: LCA is a benign lesion, which frequently occurs in the elderly. Its etiology remains confusion, however, immune dysregulation may associate with it because of the concomitance with other tumor or inflammation in some cases. The littoral cells in LCA show a hybrid endothelial-histiocytic phenotype on immunohistochemistry, therefore these cells may have features that intermediate between those of endotheliocytes and histiocytes. Emphasizing the histological findings and immunophenotypes is significant for diagnosis and differential diagnosis.


Asunto(s)
Hemangioma , Inmunohistoquímica , Inmunofenotipificación , Neoplasias del Bazo/diagnóstico , Anciano , Biomarcadores , Diagnóstico Diferencial , Femenino , Hemangioma/diagnóstico , Hemangioma/inmunología , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Neoplasias del Bazo/inmunología
4.
Acta Paediatr ; 106(2): 292-297, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27889920

RESUMEN

AIM: We investigated the expression of neuropeptide Y (NPY), NPY receptor 1 (NPYR1) and NPY receptor 2 (NPYR2) in infantile haemangiomas (IHs). METHODS: Immunohistochemical (IHC) staining was performed on proliferating IHs from six patients aged 4-13 (mean 8.7) months and involuted IHs from six patients aged 5-59 (mean 18.7) years, for the expression of NPY, NPYR1 and NPYR2. Protein and messenger ribonucleic acid expression corresponding to these proteins was investigated by Western blotting and NanoString analysis, respectively. RESULTS: IHC staining, Western blotting and NanoString analysis demonstrated the presence of NPYR1, but not NPYR2, within proliferating and involuted IHs. IHC staining showed NPYR1 was expressed by B and T lymphocytes expressing CD45 and mast cells expressing tryptase. IHC staining demonstrated the presence of NPY on the NPYR1+ cells, but it was not detected by Western blotting or NanoString analysis. CONCLUSION: NPYR1, but not NPYR2, was present in IHs. The localisation of NPYR1 to B and T lymphocytes and mast cells suggests its role in the biology of IHs. The demonstration of NPY on the NPYR1+ cells, without active transcription, suggests that NPY was not being produced within IHs.


Asunto(s)
Linfocitos B/metabolismo , Hemangioma/inmunología , Mastocitos/metabolismo , Receptores de Neuropéptido Y/metabolismo , Linfocitos T/metabolismo , Adolescente , Adulto , Western Blotting , Recuento de Células , Niño , Preescolar , Expresión Génica , Hemangioma/metabolismo , Hemangioma/patología , Humanos , Inmunohistoquímica , Adulto Joven
6.
Angiogenesis ; 18(3): 347-59, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26026674

RESUMEN

BACKGROUND: Endothelial colony forming cells (ECFC) represent a subpopulation of endothelial progenitor cells involved in endothelial repair. The activation of procoagulant mechanisms associated with the vascular wall's inflammatory responses to injury plays a crucial role in the induction and progression of atherosclerosis. However, little is known about ECFC proinflammatory potential. AIMS: To explore the role of the thrombin receptor PAR-1 proinflammatory effects on ECFC chemotaxis/recruitment capacity. METHODS AND RESULTS: The expression of 30 genes known to be associated with inflammation and chemotaxis was quantified in ECFC by real-time qPCR. PAR-1 activation with the SFLLRN peptide (PAR-1-ap) resulted in a significant increase in nine chemotaxis-associated genes expression, including CCL2 and CCL3 whose receptors are present on ECFC. Furthermore, COX-2 expression was found to be dramatically up-regulated consequently to PAR-1 activation. COX-2 silencing with the specific COX-2-siRNA also triggered down-regulation of the nine target genes. Conditioned media (c.m.) from control-siRNA- and COX-2-siRNA-transfected ECFC, stimulated or not with PAR-1-ap, were produced and tested on ECFC capacity to recruit leukocytes in vitro as well in the muscle of ischemic hindlimb in a preclinical model. The capacity of the c.m. from ECFC stimulated with PAR-1-ap to recruit leukocytes was abrogated when COX-2 gene expression was silenced in vitro (in terms of U937 cells migration and adhesion to endothelial cells) as well as in vivo. Finally, the postnatal vasculogenic stem cell derived from infantile hemangioma tumor (HemSC) incubated with PAR-1-ap increased leukocyte recruitment in Matrigel(®) implant. CONCLUSIONS: PAR-1 activation in ECFC increases chemotactic gene expression and leukocyte recruitment at ischemic sites through a COX-2-dependent mechanism.


Asunto(s)
Quimiotaxis , Ciclooxigenasa 2/metabolismo , Leucocitos/citología , Receptor PAR-1/metabolismo , Células Madre/citología , Animales , Aterosclerosis/metabolismo , Medios de Cultivo Condicionados , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Células Endoteliales/citología , Sangre Fetal/citología , Citometría de Flujo , Regulación de la Expresión Génica , Hemangioma/inmunología , Humanos , Inflamación , Leucocitos/metabolismo , Masculino , Ratones , Ratones Desnudos , ARN Interferente Pequeño/metabolismo , Células U937
7.
J Clin Pathol ; 68(10): 812-8, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26067666

RESUMEN

AIMS: Interstitial CD45+ cells and T lymphocytes have previously been demonstrated within infantile haemangioma (IH). This study investigated the expression of B and T lymphocyte markers by the CD45+ population, and the expression of Thy-1, a marker of thymocyte progenitors, which have the ability to give rise to both B and T cells. METHODS: Immunohistochemical (IHC) staining was performed on proliferating and involuted IHs for the expression of CD45, CD3, CD20, CD79a, Thy-1 and CD34. The presence of mRNA corresponding to CD45, CD3G, CD20 and Thy-1 was confirmed by reverse transcriptase-polymerase chain reaction in snap-frozen IH tissues. Cell counting of 3,3-diaminobenzidine IHC-stained slides was performed on CD45+ only cells and dually stained CD45+/CD3+ cells or CD45+/CD20+ cells and analysed statistically. In situ hybridisation and mass spectrometry were also performed to confirm the presence and abundance of Thy-1, respectively. RESULTS: IHC staining showed a subpopulation of CD45+ interstitial cells that expressed the T lymphocyte marker, CD3, and another subpopulation that expressed the B lymphocyte marker, CD20, in proliferating and diminished in involuted IHs. The abundant expression of Thy-1 on the endothelium of proliferating, but not involuted IH, was demonstrated by IHC staining and confirmed by in situ hybridisation and mass spectrometry. CONCLUSIONS: Both B and T lymphocytes are present within the interstitium of proliferating and involuted IH. The expression of Thy-1 by the endothelium suggests that B and T cells in IH may have originated from within the lesion, rather than migrating from the peripheral circulation.


Asunto(s)
Subgrupos de Linfocitos B/inmunología , Biomarcadores de Tumor/análisis , Hemangioma/inmunología , Subgrupos de Linfocitos T/inmunología , Antígenos CD20/análisis , Subgrupos de Linfocitos B/patología , Biomarcadores de Tumor/genética , Complejo CD3/análisis , Linaje de la Célula , Proliferación Celular , Células Endoteliales/inmunología , Células Endoteliales/patología , Hemangioma/genética , Hemangioma/patología , Humanos , Inmunohistoquímica , Inmunofenotipificación , Hibridación in Situ , Lactante , Antígenos Comunes de Leucocito/análisis , Antígenos Comunes de Leucocito/genética , Fenotipo , ARN Mensajero/análisis , Reacción en Cadena en Tiempo Real de la Polimerasa , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Subgrupos de Linfocitos T/patología , Espectrometría de Masas en Tándem , Antígenos Thy-1/análisis , Antígenos Thy-1/genética
8.
Lab Invest ; 95(7): 765-80, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25961170

RESUMEN

Microvascular endothelial cells cultured in three-dimensional hydrogel scaffolds form a network of microvessel structures when implanted subcutaneously in mice, inosculate with host vessels, and over time remodel into large ectatic vascular structures resembling hemangiomas. When compared with infantile hemangiomas, similarities were noted, including a temporal progression from a morphological appearance of a proliferative phase to the appearance of an involuted phase, mimicking the proliferative and involutional phases of infantile hemangioma. Consistent with the progression of a proliferative phase to an involuted phase, both the murine implants and human biopsy tissue exhibit reduced expression of Ajuba, YAP, and Survivin labeling as they progressed over time. Significant numbers of CD45+, CD11b+, Mac3+ mononuclear cells were found at the 2-week time point in our implant model that correlated with the presence of CD45+, CD68+ mononuclear cells observed in biopsies of human proliferative-phase hemangiomas. At the 4-week time point in our implant model, only small numbers of CD45+ cells were detected, which again correlated with our findings of significantly diminished CD45+, CD68+ mononuclear cells in human involutional-phase hemangiomas. The demonstration of mononuclear cell infiltration transiently in the proliferative phase of these lesions suggests that the vascular proliferation and/or regression may be driven in part by an immune response. Gross and microscopic morphological appearances of human proliferative and involutional hemangiomas and our implant model correlate well with each other as do the expression levels of Hippo pathway components (Ajuba and YAP) and Survivin and correlate with proliferation in these entities. Inhibitors of Survivin and Ajuba (which we have demonstrated to inhibit proliferation and increase apoptosis in murine hemangioendothelioma cell tissue culture) may have potential as other beneficial treatments for proliferating infantile hemangiomas. This implant model may have potential as a modest through-put screen for testing and development of therapeutics targeted at the proliferative phase of infantile hemangiomas, reducing the subsequent postinvolutional scarring or deformities sometimes associated with these lesions.


Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/metabolismo , Modelos Animales de Enfermedad , Hemangioma/metabolismo , Proteínas Inhibidoras de la Apoptosis/metabolismo , Proteínas con Dominio LIM/metabolismo , Fosfoproteínas/metabolismo , Proteínas Represoras/metabolismo , Animales , Proteínas de Ciclo Celular , Células Cultivadas , Niño , Preescolar , Células Endoteliales/metabolismo , Femenino , Hemangioma/inmunología , Humanos , Hidrogel de Polietilenoglicol-Dimetacrilato , Lactante , Macrófagos/metabolismo , Masculino , Ratones Endogámicos C57BL , Survivin , Análisis de Matrices Tisulares , Andamios del Tejido , Proteínas Señalizadoras YAP
9.
World J Surg Oncol ; 11: 300, 2013 Nov 23.
Artículo en Inglés | MEDLINE | ID: mdl-24266957

RESUMEN

BACKGROUND: Urea injection has been used in hemangioma treatment as sclerotherapy. It shrinks vascular endothelial cells and induces degeneration, necrosis, and fibrosis. However, this treatment still has disadvantages, such as lacking targeting and difficulty in controlling the urea dosage. Thus, we designed a urea immunoliposome to improve the efficiency of treatment. METHODS: The urea liposome was prepared by reverse phase evaporation. Furthermore, the urea immunoliposome was generated by coupling the urea liposome with a vascular endothelial growth factor receptor (VEGFR) monoclonal antibody using the glutaraldehyde cross-linking method. The influence of the urea immunoliposome on cultured human hemangioma vascular endothelial cells was observed preliminarily. RESULTS: Urea immunoliposomes showed typical liposome morphology under a transmission electron microscope, with an encapsulation percentage of 54.4% and a coupling rate of 36.84% for anti-VEGFR. Treatment with the urea immunoliposome significantly inhibited the proliferation of hemangioma vascular endothelial cells (HVECs) in a time- and dose-dependent manner. CONCLUSIONS: The urea immunoliposome that we developed distinctly and persistently inhibited the proliferation of HVECs and is expected to be used in clinical hemangioma treatment.


Asunto(s)
Anticuerpos Monoclonales/farmacología , Proliferación Celular/efectos de los fármacos , Sistemas de Liberación de Medicamentos , Células Endoteliales/efectos de los fármacos , Hemangioma/tratamiento farmacológico , Liposomas , Receptores de Factores de Crecimiento Endotelial Vascular/inmunología , Urea/química , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/inmunología , Hemangioma/irrigación sanguínea , Hemangioma/inmunología , Humanos , Células Tumorales Cultivadas
10.
J Clin Pathol ; 66(12): 1058-64, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23986554

RESUMEN

AIMS: The pathogenesis of infantile haemangiomas (IHs) is still far from clear despite the fact that they are common vascular tumours distinctive for their perinatal presentation, rapid growth during the first year of life and subsequent slow involution. AIMS: To determine the role of M2-polarised macrophages in IHs. METHODS: M2-polarised macrophages were initially identified in 20 specimens of IHs by both immunochemistry and immunofluorescence for CD68 and CD163. The immunopositive M2-polarised macrophages in different phases of IHs were quantified, and further analysed for their correlations with the expression levels of Ki67, vascular endothelial growth factor (VEGF) and macrophage colony-stimulating factor (M-CSF). RESULTS: The infiltrating macrophages in proliferative IHs were predominantly CD68/CD163, thus of the M2-polarised phenotype, whereas the density of these cells was significantly decreased in the involuting IHs. The high density of M2-polarised macrophages in proliferative IHs was closely correlated with overexpression of M-CSF, one of the cytokines considered to induce macrophages to polarise towards an M2 phenotype. The infiltrating M2-polarised macrophages probably contributed to the proliferation and angiogenesis of haemangioma endothelial cells, as evidenced by their close correlations with the immunoreactivities of Ki67 and VEGF. CONCLUSIONS: Results indicate that the infiltrating M2-polarised macrophages may contribute to the progression of IHs by promoting the angiogenic process.


Asunto(s)
Hemangioma/patología , Antígeno Ki-67/inmunología , Factor Estimulante de Colonias de Macrófagos/inmunología , Macrófagos/inmunología , Factor A de Crecimiento Endotelial Vascular/inmunología , Antígenos CD/inmunología , Antígenos CD/metabolismo , Antígenos de Diferenciación Mielomonocítica/inmunología , Antígenos de Diferenciación Mielomonocítica/metabolismo , Polaridad Celular , Proliferación Celular , Progresión de la Enfermedad , Femenino , Técnica del Anticuerpo Fluorescente , Hemangioma/irrigación sanguínea , Hemangioma/inmunología , Hemangioma/metabolismo , Humanos , Inmunohistoquímica , Lactante , Antígeno Ki-67/metabolismo , Factor Estimulante de Colonias de Macrófagos/metabolismo , Macrófagos/citología , Macrófagos/fisiología , Masculino , Neovascularización Patológica , Fenotipo , Pronóstico , Receptores de Superficie Celular/inmunología , Receptores de Superficie Celular/metabolismo , Factor A de Crecimiento Endotelial Vascular/metabolismo
11.
Am J Dermatopathol ; 35(1): 98-101, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22722465

RESUMEN

Microvenular hemangioma (MVH) is a rare, slowly growing, benign vascular tumor that typically presents as a solitary enlarging plaque or nodule on the trunk or the extremities of young to middle-aged adults. A minority of MVH present with multiple lesions that are either gradually or suddenly acquired (eruptive MVH). Herein, we report a case of a 53-year-old woman who progressively developed numerous bilateral MVHs presenting as enlarging, blanching, erythematous to violaceous macules, patches, and plaques over the proximal thighs and axillae. Two biopsies exhibited the irregular branching venules with inconspicuous lumina lacking endothelial atypia and associated with dermal fibrosis characteristic of MVH. Immunophenotypically, the endothelium expressed Wilms Tumor 1, CD31, CD34, and erythrocyte-type glucose transporter protein (GLUT-1) GLUT-1 focally and was negative for Human herpes virus 8 and the lymphatic marker D2-40. In addition, numerous dermal spindle cells expressing CD34 and procollagen, putative fibrocytes, surrounded the thickened dermal collagen bundles and small vessels of MVH implicating a reactive/reparative (proliferative) process due to an unrecognized cutaneous injury. A review of MVH summarizing its clinicopathologic findings and its natural history is presented.


Asunto(s)
Hemangioma/patología , Neoplasias Cutáneas/patología , Piel/irrigación sanguínea , Piel/patología , Vénulas/patología , Adolescente , Adulto , Biomarcadores de Tumor/análisis , Biopsia , Niño , Preescolar , Femenino , Hemangioma/química , Hemangioma/inmunología , Humanos , Inmunohistoquímica , Inmunofenotipificación , Masculino , Persona de Mediana Edad , Piel/química , Piel/inmunología , Neoplasias Cutáneas/química , Neoplasias Cutáneas/inmunología , Vénulas/química , Vénulas/inmunología , Adulto Joven
12.
Toxicol Pathol ; 41(5): 709-21, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23125116

RESUMEN

It is unclear whether the process of spontaneous and chemically induced hemangiosarcoma and hemangioma formation in mice involves the transformation of differentiated endothelial cells (ECs) or recruitment of multipotential bone marrow-derived hematopoietic stem cells or endothelial progenitor cells (EPCs), which show some degree of endothelial differentiation. In the present study, immunohistochemical staining for hematopoietic stem cell markers (CD45 and CD34), EC markers (vascular endothelial growth factor receptor 2 [VEGFR2], CD31, and factor VIII-related antigen), and a myeloid lineage marker (CD14) was employed to better define the origin of hemangiosarcomas and hemangiomas in mice. Staining was negative for CD45, factor VIII-related antigen, and CD14 and positive for CD34, VEGFR2, and CD31, indicating that mouse hemangiosarcomas and hemangiomas are composed of cells derived from EPCs expressing CD34, VEGFR2, and CD31 but not factor VIII-related antigen. The lack of CD45 expression suggests that mouse vascular tumors may arise from EPCs that are at a stage later than hematopoietic stem cells. Since factor VIII-related antigen expression is known to occur later than CD31 expression in EPCs, our observations may indicate that these tumor cells are arrested at a stage prior to complete differentiation.  In addition, myeloid lineage cells do not appear to contribute to hemangiosarcoma and hemangioma formation in mice.


Asunto(s)
Antígenos CD/análisis , Células Endoteliales/metabolismo , Hemangioma/metabolismo , Hemangiosarcoma/metabolismo , Células Madre Hematopoyéticas/metabolismo , Células Mieloides/metabolismo , Animales , Antígenos CD/química , Biomarcadores/análisis , Biomarcadores/química , Células Endoteliales/química , Células Endoteliales/inmunología , Femenino , Hemangioma/inducido químicamente , Hemangioma/inmunología , Hemangiosarcoma/inducido químicamente , Hemangiosarcoma/inmunología , Células Madre Hematopoyéticas/química , Células Madre Hematopoyéticas/inmunología , Inmunohistoquímica , Masculino , Ratones , Mutágenos/toxicidad , Células Mieloides/química , Células Mieloides/inmunología
14.
World J Surg Oncol ; 9: 106, 2011 Sep 19.
Artículo en Inglés | MEDLINE | ID: mdl-21929754

RESUMEN

BACKGROUND: Littoral cell angioma (LCA) is a rare vascular tumor of the spleen. Generally thought to be benign, additional cases of LCA with malignant features have been described. Thus, its malignant potential seems to vary and must be considered uncertain. The etiology remains unclear, but an immune dysregulation for the apparent association with malignancies of visceral organs or immune-mediated diseases has been proposed. CASE PRESENTATION: We report a case of LCA in a 43-year old male patient who presented with a loss of appetite and intermittent upper abdominal pain. Computed tomography showed multiple hypoattenuating splenic lesions which were hyperechogenic on abdominal ultrasound. Lymphoma was presumed and splenectomy was performed. Pathological evaluation revealed LCA. CONCLUSIONS: LCA is a rare, primary vascular neoplasm of the spleen that might etiologically be associated with immune dysregulation. In addition, it shows a striking association with synchronous or prior malignancies. With about one-third of the reported cases to date being co-existent with malignancies of visceral organs or immune-mediated diseases, this advocates for close follow-ups in all patients diagnosed with LCA. To our knowledge, this report is the first one of LCA associated with previous pulmonary sarcoidosis and hypothesizes a TNF-α related pathogenesis of this splenic tumor.


Asunto(s)
Hemangioma/inmunología , Inmunidad Celular , Sarcoidosis Pulmonar/inmunología , Neoplasias del Bazo/inmunología , Factor de Necrosis Tumoral alfa/inmunología , Adulto , Biomarcadores de Tumor/metabolismo , Biopsia , Diagnóstico Diferencial , Estudios de Seguimiento , Hemangioma/diagnóstico , Hemangioma/metabolismo , Humanos , Inmunohistoquímica , Masculino , Sarcoidosis Pulmonar/diagnóstico , Sarcoidosis Pulmonar/metabolismo , Bazo/diagnóstico por imagen , Bazo/patología , Bazo/cirugía , Esplenectomía , Neoplasias del Bazo/diagnóstico , Neoplasias del Bazo/metabolismo , Tomografía Computarizada por Rayos X , Factor de Necrosis Tumoral alfa/metabolismo
15.
Zhonghua Zhong Liu Za Zhi ; 33(12): 905-10, 2011 Dec.
Artículo en Chino | MEDLINE | ID: mdl-22340099

RESUMEN

OBJECTIVE: To investigate the significance of increasing circulating immune complex (CIC) in patients during the progression from chronic hepatitis B to hepatocellular carcinoma (HCC). METHODS: Serum levels of CIC from 20 hospitalized patients diagnosed by pathology with primary HCC, and 13 with hepatic hemangioma, and from 45 subjects with chronic HBV infection who finally developed into HCC (45 cases), and age- and gender-matched 45 subjects who kept the chronic HBV infection after consecutively followed up for 10 - 13 years by June of 2009 were quantified by ELISA. The serum levels of anti liver-kidney microsomal (anti LKM-1) antibodies were also measured by ELISA, and that of HBV-DNA were quantified by Taqman probe-based real time PCR in the followed up chronic HBV infection subjects. In the 45 chronic HBV subjects who finally developed into HCC and the 45 controls, serum samples were collected and determined at 3 time points: the baseline when the subjects were recruited, the middle point during the follow-up, and the end of follow-up. RESULTS: The serum level of CIC was significantly higher in the 20 HCC patients than that in the 13 hemangioma cases (P < 0.001). When HCC was diagnosed, the CIC concentration was significantly higher than that in the baselines (P < 0.001) in the 45 chronic HBV subjects who finally developed into HCC after the consecutively follow-up for 5 - 13 years. Of them, 36 patients (80.0%) showed progressively increased CIC during the follow-up (P < 0.001). In the controls, the CIC levels were kept relatively stable during the follow-up. Among them, 17 patients (37.8%) showed CIC slightly increased (P = 0.046). Kaplan-Meier survival analysis indicated that elevated serum CIC during the follow-up increased cumulative HCC incidence (HR = 2.77, 95%CI 1.47 - 5.22). In addition, the serum levels of anti-LKM-1 and HBV-DNA were also significantly higher in the patients who finally progressed into HCC than that in the controls and maintained at a high level during the follow-up tested at all the 3 time points. Further analysis indicated that the serum level of CIC was correlated with that of serum HBV-DNA only when HCC was diagnosed (r = 0.344, P = 0.026). CONCLUSION: Progressive increase of serum CIC level may be one of risk factors reflecting HCC development from chronic HBV infection.


Asunto(s)
Complejo Antígeno-Anticuerpo/sangre , Autoanticuerpos/sangre , Carcinoma Hepatocelular/virología , Hepatitis B Crónica/complicaciones , Neoplasias Hepáticas/virología , Carcinoma Hepatocelular/inmunología , ADN Viral/sangre , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Hemangioma/inmunología , Virus de la Hepatitis B/genética , Hepatitis B Crónica/inmunología , Humanos , Neoplasias Hepáticas/inmunología , Masculino , Persona de Mediana Edad , Factores de Riesgo
17.
Am J Dermatopathol ; 32(8): 837-40, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20881833

RESUMEN

Microvenular hemangioma (MVH) is an uncommon benign vascular neoplasm that usually occurs as a solitary asymptomatic red or purple papule, nodule, or plaque with a predilection for the upper extremities. Patients with more than 1 lesion, that is, multiple MVHs, are extremely rare. We describe the clinicopathologic features of 4 Chinese patients who had a rapidly progressive abrupt onset of numerous MVHs numbering in the tens to hundreds. Clinically, the correct diagnosis of MVH could not be made in any of our patients; however, histologic examination revealed the characteristic features of MVH. Immunohistochemical stains were performed in all cases and showed the vessel lining cells to be positive for CD34, CD31, and factor VIII-related antigen. Polymerase chain reaction for human herpesvirus-8 was negative in all cases. The differential diagnosis and review of the literature of patients with multiple MVHs are presented.


Asunto(s)
Hemangioma/patología , Neoplasias Cutáneas/patología , Vénulas/patología , Adulto , Antígenos CD34/análisis , Biomarcadores de Tumor/análisis , Biopsia , China , Diagnóstico Diferencial , Femenino , Hemangioma/inmunología , Hemangioma/virología , Herpesvirus Humano 8/genética , Herpesvirus Humano 8/aislamiento & purificación , Humanos , Inmunohistoquímica , Masculino , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/análisis , Reacción en Cadena de la Polimerasa , Valor Predictivo de las Pruebas , Neoplasias Cutáneas/inmunología , Neoplasias Cutáneas/virología , Vénulas/inmunología , Vénulas/virología , Adulto Joven , Factor de von Willebrand/análisis
18.
Arch Dermatol ; 146(7): 767-74, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20479291

RESUMEN

BACKGROUND: Infantile hemangiomas are the most common benign tumors of infancy. Up to 38% of hemangiomas require treatment with systemic medications because of complications. Corticosteroids have been the mainstay for treating such hemangiomas. However, prospective studies evaluating their immunosuppressive effects in infants with hemangiomas are lacking. OBSERVATIONS: Sixteen patients who presented to the Birthmark and Vascular Anomalies Center at the Children's Hospital of Wisconsin from November 1, 2006, through February 28, 2008, were enrolled in the study. A significant reduction in the numbers of all B- and T-lymphocyte subpopulations was observed after corticosteroid administration. CD19(+) B lymphocytes and CD4(+) T cells were significantly reduced by 8 weeks of corticosteroid therapy, whereas CD8(+) T cells were reduced at week 16 compared with baseline. Immune function was also affected because 13 and 5 patients had protective diphtheria titers and tetanus titers, respectively, 3 months after discontinuation of corticosteroid therapy compared with baseline. CONCLUSIONS: These results demonstrate that corticosteroids measurably affect both lymphocyte cell numbers and function in this patient population. Prophylaxis with the combination of trimethoprim and sulfamethoxazole should be considered in infants treated with corticosteroids for infantile hemangiomas. We also recommend that tetanus and diphtheria antibodies be checked in patients who receive oral corticosteroids during the immunization period and that additional immunization be administered if the titers are not protective after corticosteroid therapy.


Asunto(s)
Glucocorticoides/uso terapéutico , Hemangioma/inmunología , Inmunidad Celular/efectos de los fármacos , Terapia de Inmunosupresión , Prednisolona/análogos & derivados , Linfocitos T/inmunología , Relación CD4-CD8 , Relación Dosis-Respuesta a Droga , Femenino , Citometría de Flujo , Estudios de Seguimiento , Glucocorticoides/administración & dosificación , Hemangioma/tratamiento farmacológico , Humanos , Lactante , Masculino , Prednisolona/administración & dosificación , Prednisolona/uso terapéutico , Pronóstico , Estudios Prospectivos , Linfocitos T/efectos de los fármacos
19.
Pediatr Res ; 67(3): 314-9, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19924028

RESUMEN

We describe a patient, who developed during the first week of life petechiae and hematomas caused by severe thrombocytopenia and gastrointestinal bleeding due to multiple small gastric hemangiomata. Bone marrow examination showed hypermegakaryocytosis and dysmegakaryopoiesis. Alloimmune thrombocytopenia was excluded. Only 3 y later, platelet counts normalized and bleedings disappeared but small skin hemangiomata remained. Electron microscopy showed enlarged round platelets with a paucity of alpha granules similar as in GATA1-deficient patients but no GATA1 mutation was found. Immunoblot analysis showed a strong interaction between patient Igs and recombinant GATA1, GATA2, and the N finger (Nf) of GATA1. The lymphocyte transformation test with recombinant GATA1Nf was positive. In vitro culturing of normal CD34 cells with purified patient Igs showed a decreased number of megakaryocyte colonies but an increased overall size of the colonies compared with control Igs. Mice injected with patient Igs showed a reduced platelet count compared with mice injected with control Igs. Thrombopoiesis was also reduced after injection of patient Igs in transgenic zebrafish compared with control Igs. In conclusion, this study is the first report of an anti-GATA1 autoantibody leading to severe thrombocytopenia and gastrointestinal bleeding from multiple pinpoint hemangiomata.


Asunto(s)
Autoanticuerpos/sangre , Autoinmunidad , Factor de Transcripción GATA1/inmunología , Hemorragia Gastrointestinal/inmunología , Neoplasias Gastrointestinales/inmunología , Hemangioma/inmunología , Trombocitopenia/inmunología , Animales , Animales Modificados Genéticamente , Células Cultivadas , Preescolar , Femenino , Factor de Transcripción GATA1/genética , Hemorragia Gastrointestinal/sangre , Hemorragia Gastrointestinal/terapia , Neoplasias Gastrointestinales/sangre , Neoplasias Gastrointestinales/terapia , Hemangioma/sangre , Humanos , Recién Nacido , Linfocitos/inmunología , Ratones , Ratones Endogámicos NOD , Ratones SCID , Recuento de Plaquetas , Índice de Severidad de la Enfermedad , Trombocitopenia/sangre , Trombocitopenia/terapia , Trombopoyesis , Transfección , Pez Cebra/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...